osu-03012
Small moleculeexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2009 (NCT00978523)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
PDPK1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
NCC(=O)Nc1ccc(-n2nc(C(F)(F)F)cc2-c2ccc3c(ccc4ccccc43)c2)cc1- Mol. weight
- 460.46 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1650595 ↗
Also known as
- 2-amino-n-(4-(5-(2-phenanthrenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)phenyl)acetamide
- ar-12
- ar-12
- ar-12
- ar-12 compound
- osu 03012
- osu-03012
- osu-03012
- osu-03012
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00978523 | Phase 1 | Aug 1, 2009 | Arno Therapeutics, Ohio State University, Royal Marsden Hospital NHS Trust, TGen Drug Development |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arno Therapeutics | For profit | 1 | 1 | 1 | 2009 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2009 |
| TGen Drug Development | Academic/Hospital | 1 | 0 | 1 | 2009 |
4 organizations
Page 1 / 1